News

A fully human biologic, Cosentyx has been developed to directly inhibit interleukin-17A (IL-17A), a cytokine. The regulatory approval is granted for the use of the therapy, either alone

The vaccine candidate seeks to prevent anthrax in people after suspected or confirmed exposure to Bacillus anthracis. AV7909 is being assessed in adult persons between 18 and 65

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose

EP0031 is a potent next generation selective RET inhibitor (SRI) with broad activity against common RET fusions and mutations, like solvent front resistance mutations. It is jointly developed

Imcivree is a melanocortin-4 receptor (MC4R) agonist which is indicated for chronic weight management in adult and paediatric patients aged six years and above with monogenic or syndromic

VBI-1901 is a new cancer vaccine immunotherapeutic candidate that uses cytomegalovirus (CMV) as a foreign viral antigen approach to treat cancer by expressing two highly immunogenic CMV antigens,

Atogepant is an oral calcitonin gene-related peptide [CGRP] receptor antagonist (gepant) which has been specifically developed as the preventive migraine treatment. In September last year, the drug received

The funding round was co-led by an industrial investment firm and MSA Capital. Sherpa Healthcare Partners, 3H Health Investment, and the company’s existing investors Quan Capital and Cenova

The medicine is said to be the first and only specific interleukin-23 (IL-23) inhibitor approved for treating moderately to severely active CD in adults. The approval follows the